

LISTING OF CLAIMS

1-51. (Canceled)

52. (Currently amended) A method of delivering an antibody or a fragment thereof to a subject mammal without triggering an anti-idiotypic response directed against said antibody in said mammal, said method comprising transplanting a genetically modified mammal cell which comprises a polynucleotide comprising:

(i) a ~~polynucleotide~~ nucleotide sequence encoding ~~said an~~ antibody or fragment thereof, ~~and to be delivered;~~

(ii) a promoter sequence controlling expression of the ~~polynucleotide~~ nucleotide sequence from (i) in the cell, and;

(iii) an element guaranteeing the secretion of the encoded antibody or fragment thereof;

wherein said polynucleotide is expressed and the cell secretes the encoded antibody or fragment thereof such that the antibody or fragment thereof reaches the blood circulation of the subject mammal; ~~and wherein the said cell is a cell not specialized for the production of antibodies and able to a long life in the mamal's subject, preferably at least several months to several years up to until lifetime to the patient, which has the ability (a) to secrete proteins, (b) to live in the mammal subject, and wherein said cell derives from the subject mammal or from another mammal, which is a compatible donor, or is made compatible for an organ transplant.~~

53. (Previously presented) The method of claim 52, wherein the cell is selected from the group consisting of keratinocytes, hepatocytes, skin fibroblasts, myoblasts, endothelial cells and hematopoietic stem cells.

54. (Canceled)

55 (Previously presented) The method of claim 52, wherein the cell is capable of differentiating into a tissue but retains the ability to secrete the antibody.

56-59. (Canceled)

60. (Currently amended) The method of claim 52, wherein the antibody produced by cells ~~which~~ that are not specialized for the production of antibodies display a thermodynamic and kinetic properties ~~identical to those initially produced by plasmocytes~~ of binding similar to those of the antibody produced by B-cell lineage cells which are naturally specialized in the production of antibodies, as assayed by measurement of on (k_{on}) and off (k_{off}) kinetic binding constants and of association (K_A) and dissociation (K_D) constants, respectively.

61. (Previously presented) The method of claim 52, wherein antibody or fragment thereof reaching the blood circulation of a mammal subject is present in a quantity which is therapeutically effective.